Company intelligence / Profile preview

Achillion Pharmaceuticals

Blue Bell, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Before its acquisition, Achillion was a clinical-stage biopharmaceutical company developing oral small molecule inhibitors of complement factor D for alternative pathway-mediated rare diseases; its lead drug danicopan (ACH-4471) was in phase 2 for paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis, with additional factor D inhibitors and antiviral programs in earlier stages.[1][2][7]

Therapeutic areas: HematologyNephrologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Ora, Inc. (license agreement for ACH-702)GCA Therapeutics, Ltd (license agreement for elvucitabine)Evotec OAI (clinical compound manufacturing partner)

Beyond the preview

Go deeper on Achillion Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Achillion Pharmaceuticals.

Explore the full profile